Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Anderson

Showing results (411-420 of 474) with videos related to

Pageof 48
Sort By:
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society|November 8, 2024
Prior knowledge-guided vision-transformer-based unsupervised domain adaptation for intubation prediction in lung disease at one weekJunlin Yang, John Anderson Garcia Henao, Nicha Dvornek, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 20, 2023
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized TrialSorena Kiani-Alikhan, Richard Gower, Timothy Craig, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Critical Reviews in Oncology/Hematology|August 30, 2008
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approachJohn M Fitzpatrick, John Anderson, Cora N Sternberg, et al.
Endoscopy|June 7, 2023
Curriculum for training in endoscopic mucosal resection in the colon: European Society of Gastrointestinal Endoscopy (ESGE) Position StatementDavid J Tate, Maria Eva Argenziano, John Anderson, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
Advances in Therapy|June 12, 2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyJonathan A Bernstein, Stephen D Betschel, Paula J Busse, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 3, 2018
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary AngioedemaWilliam R Lumry, Timothy Craig, Bruce Zuraw, et al.
Nature Communications|August 30, 2020
Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunityYura Grabovska, Alan Mackay, Patricia O'Hare, et al.
Pageof 48

Showing results (411-420 of 474) with videos related to

Sort By:
Pageof 48
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Computerized Medical Imaging and Graphics : the Official Journal of the Computerized Medical Imaging Society|November 8, 2024
Prior knowledge-guided vision-transformer-based unsupervised domain adaptation for intubation prediction in lung disease at one weekJunlin Yang, John Anderson Garcia Henao, Nicha Dvornek, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 20, 2023
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized TrialSorena Kiani-Alikhan, Richard Gower, Timothy Craig, et al.
Orphanet Journal of Rare Diseases|February 16, 2021
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Critical Reviews in Oncology/Hematology|August 30, 2008
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approachJohn M Fitzpatrick, John Anderson, Cora N Sternberg, et al.
Endoscopy|June 7, 2023
Curriculum for training in endoscopic mucosal resection in the colon: European Society of Gastrointestinal Endoscopy (ESGE) Position StatementDavid J Tate, Maria Eva Argenziano, John Anderson, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
Advances in Therapy|June 12, 2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyJonathan A Bernstein, Stephen D Betschel, Paula J Busse, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 3, 2018
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary AngioedemaWilliam R Lumry, Timothy Craig, Bruce Zuraw, et al.
Nature Communications|August 30, 2020
Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunityYura Grabovska, Alan Mackay, Patricia O'Hare, et al.
Pageof 48